Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | How hemophilia care has changed over the years

Alok Srivastava • 11 Jul 2022
ISTH 2022
Hemophilia Non-Malignant Antibodies Emicizumab Fitusiran

Alok Srivastava, MD, FRACP, FRCPA, FRCP, Christian Medical College, Vellore, India, comments on how hemophilia care and therapeutic options for patients have changed over the years, drawing focus on the promise of agents such as emicizumab and fitusiran. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Alok Srivastava

1:48
The promise of fitusiran for the treatment of patients with hemophilia A and B
Alok Srivastava • 11 Jul 2022
1:23
The safety and efficacy of eptacog beta in patients with hemophilia
Alok Srivastava • 11 Jul 2022
1:43
The safety and efficacy of fitusiran prophylaxis in patients with hemophilia A and B
Alok Srivastava • 11 Jul 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals